Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Alnylam and Monsanto Form Strategic Alliance

Published: Wednesday, September 12, 2012
Last Updated: Wednesday, September 12, 2012
Bookmark and Share
Companies announce collaboration with aim to advance biological technologies in the field of agriculture.

The new alliance brings Alnylam’s broad RNAi-based intellectual property (IP) and proprietary technologies to Monsanto’s new BioDirect™ technology, which aims to deliver innovative biological solutions for farmers.

Under the terms of the agreement, Monsanto receives worldwide, exclusive rights to use Alnylam’s platform technology and IP in the field of agriculture, including the ability to grant sublicenses. Monsanto will pay Alnylam $29.2 million in upfront payments. In addition, Alnylam is eligible to receive milestone payments and additional funding for collaborative research efforts. Further, Alnylam is eligible to receive royalty payments on products utilizing Alnylam technology and IP. Moreover, Monsanto becomes Alnylam’s strategic partner in agriculture for a 10-year period.

“We are very pleased to partner with Alnylam, a leading technology company with unparalleled intellectual property and a technology platform that will support our work in agricultural biologicals, introduced earlier this year with BioDirect technology,” said Tom Adams, Vice President of Chemistry Technology at Monsanto. “We believe biological products have great promise in agriculture and we are excited to be collaborating with Alnylam in this area.”

“There could be no stronger partner for these applications, as Monsanto has a deep commitment to innovation and scientific excellence, and to the advancement of technologies to improve agriculture,” said Rachel Meyers, Ph.D., Vice President, Research and RNAi Lead Development at Alnylam. “This new alliance furthers our vision for RNAi technologies across a broad range of applications and is representative of our passion to pioneer these new frontiers. While we remain focused on the advancement of RNAi therapeutics as a new class of innovative medicines – and, specifically our ‘Alnylam 5x15’ product strategy – this collaboration with Monsanto enables broader uses of Alnylam intellectual property and technologies for additional value creation.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Monsanto Invests $20 Million in Integrated Technology Centers
Investment aims to transform plant breeding and deliver improved ag solutions to farmers.
Thursday, November 06, 2014
Monsanto Acquires Select Assets of Agradis, Inc. to Support Work in Agricultural Biologicals
Monsanto Company today announced it has purchased select assets of Agradis, Inc. (Agradis), a privately held company focused on developing sustainable agricultural solutions. Monsanto's purchase includes the Agradis name and its collection of microbes that can improve crop productivity. Monsanto has also acquired the company's R&D site in La Jolla, California. Additional details were not disclosed.
Thursday, January 31, 2013
Latin America Seed Growth Lifts Monsanto to Stronger-Than-Expected First Quarter
Record number of pipeline advancements underscore R&D leadership; strong U.S. seed order book reinforces positive momentum.
Thursday, January 05, 2012
Monsanto Reports Steady Growth in Fiscal Second-Quarter 2011 as Sales, Volumes Improve, an Industrial Info News Alert
Net income for the quarter was reported to be $1.02 billion, a 14.66% increase from second-quarter 2010.
Friday, April 08, 2011
New GM technology to herald next cotton revolution
US based seeds biotech company, Monsanto and its Indian partner Mahyco, are conducting field trials of a new generation of GM cotton seeds
Monday, August 09, 2010
Biotech Soybeans Promise Heart Benefits
'Engineered to be high in omega-3 fatty acids, these soybeans could change negative perceptions of genetically modified foods'
Friday, January 15, 2010
Biotech leader Monsanto jumps back into wheat
Five years after shelving a controversial biotech wheat product, Monsanto Co (MON.N) said on Tuesday it is jumping back into the wheat business, paying $45 million to acquire WestBred LLC, a specialist in wheat germplasm.
Tuesday, July 14, 2009
Scientific News
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!